Next Article in Journal
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
Previous Article in Journal
Photoprotective Effects of Selected Amino Acids on Naproxen Photodegradation in Aqueous Media
Open AccessReview

Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization

1
Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy
2
Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126 Torino, Italy
*
Author to whom correspondence should be addressed.
Those authors contributed equally.
Pharmaceuticals 2020, 13(7), 136; https://doi.org/10.3390/ph13070136
Received: 8 June 2020 / Revised: 26 June 2020 / Accepted: 26 June 2020 / Published: 27 June 2020
(This article belongs to the Section Pharmacology)
Exogenous human follicle-stimulating hormone (hFSH), either derived from extraction and purification from the urine or obtained by recombinant technology in the form of follitropin α, β and δ (rFSH), has been used for decades in the treatment of infertility. The main applications of FSH treatment in the woman have been, and still are, ovulation induction in oligo-anovulatory subjects, and stimulation of the development of a cohort of follicles in patients undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF). In the last years, two biosimilars of follitropin alfa, rFSH compounds structurally and functionally similar to the originator, have been approved and marketed for clinical use in Europe. Moreover, some other rFSH biosimilars are currently under investigation. The objective of this article is to review the available evidences comparing the efficacy, safety, and cost-effectiveness of rFSH follitropin alpha originator with its biosimilars, discussing the clinical trials that allowed biosimilars to get registration and marketing authorization. View Full-Text
Keywords: recombinant human follicle-stimulating hormone (r-hFSH); r-hFSH biosimilars; controlled ovarian stimulation; in vitro fertilization recombinant human follicle-stimulating hormone (r-hFSH); r-hFSH biosimilars; controlled ovarian stimulation; in vitro fertilization
Show Figures

Figure 1

MDPI and ACS Style

Bergandi, L.; Canosa, S.; Carosso, A.R.; Paschero, C.; Gennarelli, G.; Silvagno, F.; Benedetto, C.; Revelli, A. Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. Pharmaceuticals 2020, 13, 136.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop